Clonal Relatedness and Mutational Differences between Upper Tract and Bladder Urothelial Carcinoma
To investigate genomic differences between urothelial carcinomas of the upper tract (UTUC) and bladder (UCB), with a focus on defining the clonal relatedness of temporally distinct tumors. We prospectively sequenced tumors and matched germline DNA using targeted next-generation sequencing methods. T...
Saved in:
Published in | Clinical cancer research Vol. 25; no. 3; pp. 967 - 976 |
---|---|
Main Authors | , , , , , , , , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
01.02.2019
|
Subjects | |
Online Access | Get full text |
ISSN | 1078-0432 1557-3265 1557-3265 |
DOI | 10.1158/1078-0432.CCR-18-2039 |
Cover
Abstract | To investigate genomic differences between urothelial carcinomas of the upper tract (UTUC) and bladder (UCB), with a focus on defining the clonal relatedness of temporally distinct tumors.
We prospectively sequenced tumors and matched germline DNA using targeted next-generation sequencing methods. The cohort included 195 UTUC patients and 454 UCB patients. For a subgroup of 29 patients with UTUC and a history of a subsequent UCB, both tumors were analyzed to assess their clonal relatedness.
With the progression to higher UTUC clinical state, there were fewer alterations in the RTK/RAS pathway but more alterations in TP53/MDM2. Compared with UCB,
and
were less frequently altered in UTUC (26% vs. 46%, 3% vs. 20%, 8% vs. 19%, respectively;
< 0.001), whereas
and
were more frequently altered (40% vs. 26%, 12% vs. 4%, respectively;
< 0.001). On the basis of an integrated analysis of tumor mutational burden, MSIsensor score and mutational signature, 7.2% of UTUC tumors were classified as MSI-high/MMR-deficient (MSI-H/dMMR). The risk of bladder recurrence after UTUC was significantly associated with mutations in
and
. Comparison of UCB with corresponding UTUC tumors from the same patient supports their clonal relatedness.
UTUC and UCB exhibit significant differences in the prevalence of common genomic alterations. In individual patients with a history of both tumors, UCB and UTUC were always clonally related. Genomic characterization of UTUC provides information regarding the risk of bladder recurrence and can identify tumors associated with Lynch syndrome. |
---|---|
AbstractList | To investigate genomic differences between urothelial carcinomas of the upper tract (UTUC) and bladder (UCB), with a focus on defining the clonal relatedness of temporally distinct tumors.
We prospectively sequenced tumors and matched germline DNA using targeted next-generation sequencing methods. The cohort included 195 UTUC patients and 454 UCB patients. For a subgroup of 29 patients with UTUC and a history of a subsequent UCB, both tumors were analyzed to assess their clonal relatedness.
With the progression to higher UTUC clinical state, there were fewer alterations in the RTK/RAS pathway but more alterations in TP53/MDM2. Compared with UCB,
and
were less frequently altered in UTUC (26% vs. 46%, 3% vs. 20%, 8% vs. 19%, respectively;
< 0.001), whereas
and
were more frequently altered (40% vs. 26%, 12% vs. 4%, respectively;
< 0.001). On the basis of an integrated analysis of tumor mutational burden, MSIsensor score and mutational signature, 7.2% of UTUC tumors were classified as MSI-high/MMR-deficient (MSI-H/dMMR). The risk of bladder recurrence after UTUC was significantly associated with mutations in
and
. Comparison of UCB with corresponding UTUC tumors from the same patient supports their clonal relatedness.
UTUC and UCB exhibit significant differences in the prevalence of common genomic alterations. In individual patients with a history of both tumors, UCB and UTUC were always clonally related. Genomic characterization of UTUC provides information regarding the risk of bladder recurrence and can identify tumors associated with Lynch syndrome. To investigate genomic differences between urothelial carcinomas of the upper tract (UTUC) and bladder (UCB), with a focus on defining the clonal relatedness of temporally distinct tumors.PURPOSETo investigate genomic differences between urothelial carcinomas of the upper tract (UTUC) and bladder (UCB), with a focus on defining the clonal relatedness of temporally distinct tumors.We prospectively sequenced tumors and matched germline DNA using targeted next-generation sequencing methods. The cohort included 195 UTUC patients and 454 UCB patients. For a subgroup of 29 patients with UTUC and a history of a subsequent UCB, both tumors were analyzed to assess their clonal relatedness.EXPERIMENTAL DESIGNWe prospectively sequenced tumors and matched germline DNA using targeted next-generation sequencing methods. The cohort included 195 UTUC patients and 454 UCB patients. For a subgroup of 29 patients with UTUC and a history of a subsequent UCB, both tumors were analyzed to assess their clonal relatedness.With the progression to higher UTUC clinical state, there were fewer alterations in the RTK/RAS pathway but more alterations in TP53/MDM2. Compared with UCB, TP53, RB1, and ERBB2 were less frequently altered in UTUC (26% vs. 46%, 3% vs. 20%, 8% vs. 19%, respectively; Q < 0.001), whereas FGFR3 and HRAS were more frequently altered (40% vs. 26%, 12% vs. 4%, respectively; Q < 0.001). On the basis of an integrated analysis of tumor mutational burden, MSIsensor score and mutational signature, 7.2% of UTUC tumors were classified as MSI-high/MMR-deficient (MSI-H/dMMR). The risk of bladder recurrence after UTUC was significantly associated with mutations in FGFR3, KDM6A, CCND1, and TP53. Comparison of UCB with corresponding UTUC tumors from the same patient supports their clonal relatedness.RESULTSWith the progression to higher UTUC clinical state, there were fewer alterations in the RTK/RAS pathway but more alterations in TP53/MDM2. Compared with UCB, TP53, RB1, and ERBB2 were less frequently altered in UTUC (26% vs. 46%, 3% vs. 20%, 8% vs. 19%, respectively; Q < 0.001), whereas FGFR3 and HRAS were more frequently altered (40% vs. 26%, 12% vs. 4%, respectively; Q < 0.001). On the basis of an integrated analysis of tumor mutational burden, MSIsensor score and mutational signature, 7.2% of UTUC tumors were classified as MSI-high/MMR-deficient (MSI-H/dMMR). The risk of bladder recurrence after UTUC was significantly associated with mutations in FGFR3, KDM6A, CCND1, and TP53. Comparison of UCB with corresponding UTUC tumors from the same patient supports their clonal relatedness.UTUC and UCB exhibit significant differences in the prevalence of common genomic alterations. In individual patients with a history of both tumors, UCB and UTUC were always clonally related. Genomic characterization of UTUC provides information regarding the risk of bladder recurrence and can identify tumors associated with Lynch syndrome.CONCLUSIONSUTUC and UCB exhibit significant differences in the prevalence of common genomic alterations. In individual patients with a history of both tumors, UCB and UTUC were always clonally related. Genomic characterization of UTUC provides information regarding the risk of bladder recurrence and can identify tumors associated with Lynch syndrome. |
Author | Dalbagni, Guido Ostrovnaya, Irina Al-Ahmadie, Hikmat Rosenberg, Jonathan E. Cha, Eugene K. Arcila, Maria E. Drill, Esther N. Iyer, Gopa Pietzak, Eugene J. Audenet, François Donoghue, Mark T.A. Taylor, Barry S. Bochner, Bernard H. Isharwal, Sumit Bagrodia, Aditya Sfakianos, John P. Coleman, Jonathan A. Solit, David B. Berger, Michael F. Murugan, Paari Bajorin, Dean F. Hechtman, Jaclyn F. Donahue, Timothy F. |
AuthorAffiliation | 5 Department of Urology, UT Southwestern Medical Center, Dallas, USA 8 Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, USA 1 Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, USA 2 Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, USA 7 Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA 6 Department of Laboratory Medicine and Pathology, University of Minnesota, USA 4 Department of Urology, Mount Sinai Hospital, New York, USA 9 Weil Cornell Medical College, New York, USA 3 Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, USA |
AuthorAffiliation_xml | – name: 5 Department of Urology, UT Southwestern Medical Center, Dallas, USA – name: 2 Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, USA – name: 6 Department of Laboratory Medicine and Pathology, University of Minnesota, USA – name: 3 Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, USA – name: 9 Weil Cornell Medical College, New York, USA – name: 8 Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, USA – name: 1 Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, USA – name: 4 Department of Urology, Mount Sinai Hospital, New York, USA – name: 7 Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA |
Author_xml | – sequence: 1 givenname: François orcidid: 0000-0001-5722-2075 surname: Audenet fullname: Audenet, François – sequence: 2 givenname: Sumit surname: Isharwal fullname: Isharwal, Sumit – sequence: 3 givenname: Eugene K. surname: Cha fullname: Cha, Eugene K. – sequence: 4 givenname: Mark T.A. surname: Donoghue fullname: Donoghue, Mark T.A. – sequence: 5 givenname: Esther N. surname: Drill fullname: Drill, Esther N. – sequence: 6 givenname: Irina surname: Ostrovnaya fullname: Ostrovnaya, Irina – sequence: 7 givenname: Eugene J. surname: Pietzak fullname: Pietzak, Eugene J. – sequence: 8 givenname: John P. surname: Sfakianos fullname: Sfakianos, John P. – sequence: 9 givenname: Aditya surname: Bagrodia fullname: Bagrodia, Aditya – sequence: 10 givenname: Paari surname: Murugan fullname: Murugan, Paari – sequence: 11 givenname: Guido surname: Dalbagni fullname: Dalbagni, Guido – sequence: 12 givenname: Timothy F. surname: Donahue fullname: Donahue, Timothy F. – sequence: 13 givenname: Jonathan E. surname: Rosenberg fullname: Rosenberg, Jonathan E. – sequence: 14 givenname: Dean F. surname: Bajorin fullname: Bajorin, Dean F. – sequence: 15 givenname: Maria E. surname: Arcila fullname: Arcila, Maria E. – sequence: 16 givenname: Jaclyn F. surname: Hechtman fullname: Hechtman, Jaclyn F. – sequence: 17 givenname: Michael F. surname: Berger fullname: Berger, Michael F. – sequence: 18 givenname: Barry S. surname: Taylor fullname: Taylor, Barry S. – sequence: 19 givenname: Hikmat surname: Al-Ahmadie fullname: Al-Ahmadie, Hikmat – sequence: 20 givenname: Gopa surname: Iyer fullname: Iyer, Gopa – sequence: 21 givenname: Bernard H. surname: Bochner fullname: Bochner, Bernard H. – sequence: 22 givenname: Jonathan A. surname: Coleman fullname: Coleman, Jonathan A. – sequence: 23 givenname: David B. surname: Solit fullname: Solit, David B. |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/30352907$$D View this record in MEDLINE/PubMed |
BookMark | eNqFkV1rFDEUhoO02A_9CcpcejM1Jx-TDIKg4ye0FEr3OmQyZ2wkm6zJrOK_N9tti3pTCCTkPO85Ic8JOYgpIiEvgJ4BSP0aqNItFZydDcNVC7pllPdPyDFIqVrOOnlQz_fMETkp5TulIICKp-SIUy5ZT9UxGYeQog3NFQa74BSxlMbGqbnYLnbxt6UPfp4xY3RYmhGXX4ixWW02mJvrbN1yi78PdprqzSqn5QaDr7HBZudjWttn5HC2oeDzu_2UrD59vB6-tOeXn78O785bJ5Ra2k6im7VibkTXT-NMEeTcazEqTiUVruMTIK2LKaaB28oBoIaZia7TgvFT8nbfd7Md1zg5jEu2wWyyX9v82yTrzb-V6G_Mt_TTdFz2vYLa4NVdg5x-bLEsZu2LwxBsxLQthgGTHEDIvqIv_571MOT-Yysg94DLqZSM8wMC1OwEmp0cs5NjqkAD2uwE1tyb_3LO703UJ_vwSPoPv0eh_Q |
CitedBy_id | crossref_primary_10_3389_fonc_2021_766576 crossref_primary_10_3389_fruro_2023_1229709 crossref_primary_10_3390_curroncol31110511 crossref_primary_10_3390_cancers14143537 crossref_primary_10_1016_j_jasc_2020_06_011 crossref_primary_10_1111_bju_15735 crossref_primary_10_1177_15330338231159753 crossref_primary_10_3390_cancers13174341 crossref_primary_10_3390_ijms251910348 crossref_primary_10_1002_ijc_33327 crossref_primary_10_1002_cncr_32806 crossref_primary_10_1016_j_eururo_2020_05_039 crossref_primary_10_1080_2162402X_2022_2124691 crossref_primary_10_1097_MOU_0000000000000596 crossref_primary_10_1177_00369330221134233 crossref_primary_10_1007_s10689_022_00306_z crossref_primary_10_1016_j_euf_2020_08_001 crossref_primary_10_1186_s12885_019_6227_7 crossref_primary_10_3390_cancers14194841 crossref_primary_10_1016_j_ajur_2021_06_005 crossref_primary_10_1016_j_bspc_2024_107431 crossref_primary_10_1158_2159_8290_CD_18_1196 crossref_primary_10_1038_s41588_024_02015_y crossref_primary_10_1016_j_eururo_2023_03_013 crossref_primary_10_1097_MOU_0000000000000639 crossref_primary_10_1016_j_clgc_2019_07_011 crossref_primary_10_3390_biomedicines10092223 crossref_primary_10_1002_cam4_6112 crossref_primary_10_1002_path_6265 crossref_primary_10_1016_j_clgc_2022_06_013 crossref_primary_10_1002_cncr_32804 crossref_primary_10_1016_j_euo_2024_01_013 crossref_primary_10_3233_BLC_200282 crossref_primary_10_1016_j_urolonc_2020_01_014 crossref_primary_10_1172_JCI169241 crossref_primary_10_1159_000530710 crossref_primary_10_1038_s41467_024_46320_w crossref_primary_10_3390_jcm10184197 crossref_primary_10_1002_advs_202103999 crossref_primary_10_23736_S2724_6051_24_05701_X crossref_primary_10_1080_2090598X_2021_1883810 crossref_primary_10_1016_j_ctrv_2022_102351 crossref_primary_10_1093_jjco_hyab003 crossref_primary_10_1016_j_urology_2023_11_019 crossref_primary_10_1016_j_humpath_2021_09_007 crossref_primary_10_1038_s41598_023_30356_x crossref_primary_10_3389_fimmu_2022_994594 crossref_primary_10_1007_s00795_021_00301_w crossref_primary_10_1002_kjm2_12104 crossref_primary_10_1016_j_path_2024_08_004 crossref_primary_10_1055_s_0045_1805081 crossref_primary_10_1016_j_urology_2020_07_034 crossref_primary_10_1158_1078_0432_CCR_20_4419 crossref_primary_10_1016_j_urolonc_2020_01_008 crossref_primary_10_1111_cas_14782 crossref_primary_10_1016_j_ajur_2024_10_006 crossref_primary_10_1016_j_csbj_2021_08_037 crossref_primary_10_1097_MOU_0000000000000899 crossref_primary_10_3390_jcm11154483 crossref_primary_10_1016_j_clgc_2019_08_010 crossref_primary_10_1007_s10147_020_01785_9 crossref_primary_10_1172_jci_insight_144920 crossref_primary_10_1016_j_humpath_2022_06_006 crossref_primary_10_1111_iju_15257 crossref_primary_10_3390_ijms221910612 crossref_primary_10_1016_j_urolonc_2019_11_010 crossref_primary_10_3390_jpm11111147 crossref_primary_10_1101_mcs_a003848 crossref_primary_10_1155_2022_3373851 crossref_primary_10_52420_umj_23_4_104 crossref_primary_10_1158_1078_0432_CCR_24_1583 crossref_primary_10_1200_JCO_23_01659 crossref_primary_10_1038_s41467_020_15885_7 crossref_primary_10_1186_s12894_023_01387_3 crossref_primary_10_1038_s41585_022_00578_1 crossref_primary_10_1177_00369330231151800 crossref_primary_10_1097_CAD_0000000000001200 crossref_primary_10_1097_MOU_0000000000000782 crossref_primary_10_3390_diagnostics13051004 crossref_primary_10_1172_jci_insight_128728 crossref_primary_10_1016_j_urolonc_2021_08_019 crossref_primary_10_1097_MOU_0000000000000943 crossref_primary_10_1093_pcmedi_pbaa020 crossref_primary_10_2217_fon_2021_1629 crossref_primary_10_1016_j_modpat_2023_100300 crossref_primary_10_3389_fonc_2021_779918 crossref_primary_10_4111_icu_20230066 crossref_primary_10_2147_CMAR_S445529 crossref_primary_10_1016_j_euros_2023_01_004 crossref_primary_10_1038_s41416_021_01488_6 crossref_primary_10_3390_ijms23095154 crossref_primary_10_1007_s00066_020_01640_w crossref_primary_10_3389_fonc_2023_1123776 crossref_primary_10_1016_j_eururo_2023_09_017 crossref_primary_10_12688_f1000research_26841_1 crossref_primary_10_1016_j_eururo_2024_10_024 crossref_primary_10_1038_s41419_022_04983_7 crossref_primary_10_1186_s13059_023_03026_4 crossref_primary_10_3390_genes12030333 crossref_primary_10_2217_imt_2021_0109 crossref_primary_10_1016_j_eururo_2020_04_021 crossref_primary_10_3390_jcm13216593 crossref_primary_10_1136_bmjonc_2024_000335 crossref_primary_10_1016_j_urolonc_2020_05_002 crossref_primary_10_1186_s13000_023_01405_w crossref_primary_10_1097_PAS_0000000000002331 crossref_primary_10_3390_jcm9123866 crossref_primary_10_1016_j_semradonc_2022_10_001 crossref_primary_10_3390_biomedicines11071775 crossref_primary_10_3390_cancers12020439 crossref_primary_10_1016_j_urolonc_2023_07_007 crossref_primary_10_1007_s00345_023_04701_8 crossref_primary_10_1186_s13000_021_01109_z crossref_primary_10_1038_s41585_023_00725_2 crossref_primary_10_3389_fonc_2022_1031774 crossref_primary_10_3390_curroncol29060312 crossref_primary_10_1016_j_eururo_2020_07_018 crossref_primary_10_1177_00369330221130763 crossref_primary_10_1038_s41585_019_0145_y crossref_primary_10_1038_s41467_019_10873_y crossref_primary_10_3390_cancers14071640 crossref_primary_10_3389_fonc_2021_731318 crossref_primary_10_1111_iju_14656 crossref_primary_10_1016_j_path_2024_09_003 crossref_primary_10_1002_onco_13839 crossref_primary_10_1016_j_euo_2021_11_001 crossref_primary_10_1016_S0140_6736_20_30519_5 crossref_primary_10_1016_j_clgc_2020_03_006 crossref_primary_10_1200_JCO_19_01395 crossref_primary_10_1016_j_urology_2020_06_108 crossref_primary_10_1111_bju_16405 crossref_primary_10_3390_cancers15072002 crossref_primary_10_1002_path_5306 crossref_primary_10_2196_15363 crossref_primary_10_1016_j_euo_2020_12_007 crossref_primary_10_1200_JCO_25_00179 crossref_primary_10_1186_s13059_020_02230_w crossref_primary_10_3390_curroncol29020060 crossref_primary_10_1002_ijc_32737 crossref_primary_10_1097_MOU_0000000000001025 crossref_primary_10_1007_s10147_020_01650_9 crossref_primary_10_1016_j_eururo_2024_12_006 crossref_primary_10_1097_PAS_0000000000002279 crossref_primary_10_1002_cam4_70398 crossref_primary_10_3390_cancers15092414 crossref_primary_10_1093_jjco_hyad172 crossref_primary_10_3389_fimmu_2022_1097730 crossref_primary_10_3390_biomedicines12092154 crossref_primary_10_3390_cancers13061448 crossref_primary_10_1016_j_ccell_2021_05_004 crossref_primary_10_1016_j_euo_2021_01_009 crossref_primary_10_2217_imt_2023_0028 crossref_primary_10_1016_j_ccell_2021_05_008 crossref_primary_10_4103_UROS_UROS_58_22 crossref_primary_10_1007_s00345_023_04700_9 crossref_primary_10_1111_bju_15324 crossref_primary_10_1111_bju_15566 crossref_primary_10_1158_2159_8290_CD_22_1441 crossref_primary_10_3390_cancers15020506 crossref_primary_10_3389_fpubh_2022_994351 crossref_primary_10_1002_cam4_6175 crossref_primary_10_1016_j_urolonc_2021_05_037 crossref_primary_10_1093_oncolo_oyad070 crossref_primary_10_1136_jitc_2024_010964 crossref_primary_10_3389_fonc_2022_990023 |
Cites_doi | 10.1016/j.eururo.2014.11.035 10.1200/JCO.2018.36.6_suppl.411 10.1158/1078-0432.CCR-05-0891 10.1371/journal.pone.0038863 10.1093/bioinformatics/btt755 10.1038/nature12477 10.1016/j.eururo.2017.07.036 10.1093/nar/gkw520 10.1200/JCO.2017.35.15_suppl.4511 10.1093/aje/153.5.411 10.1073/pnas.0701248104 10.1016/j.jmoldx.2014.12.006 10.1111/j.1464-410X.2012.11298.x 10.3322/caac.21442 10.1016/j.eururo.2017.05.048 10.1016/j.cell.2017.09.007 10.1200/JCO.2012.46.5740 10.1016/j.eururo.2011.05.064 10.1038/nature12965 10.1016/j.juro.2012.05.079 10.1016/S0140-6736(16)00561-4 10.1038/nm.4333 10.1001/jamaoncol.2018.0104 10.1093/jnci/djs351 10.1038/s41568-018-0043-2 10.4238/2014.February.20.12 10.1111/j.1464-410X.2009.08838.x 10.1016/j.celrep.2012.12.008 10.1016/S0022-5347(05)67019-X 10.1016/j.eururo.2015.07.039 10.1016/j.eururo.2016.05.041 10.1016/j.eururo.2008.08.008 10.1214/15-AOAS836 10.1038/sj.onc.1210934 10.1186/2193-1801-2-412 10.1038/sj.onc.1204671 10.1016/0140-6736(93)92066-3 |
ContentType | Journal Article |
Copyright | 2018 American Association for Cancer Research. |
Copyright_xml | – notice: 2018 American Association for Cancer Research. |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM |
DOI | 10.1158/1078-0432.CCR-18-2039 |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic PubMed Central (Full Participant titles) |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
DatabaseTitleList | MEDLINE MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1557-3265 |
EndPage | 976 |
ExternalDocumentID | PMC6359971 30352907 10_1158_1078_0432_CCR_18_2039 |
Genre | Research Support, Non-U.S. Gov't Journal Article Research Support, N.I.H., Extramural |
GrantInformation_xml | – fundername: NCI NIH HHS grantid: P30 CA008748 – fundername: NCI NIH HHS grantid: R01 CA182587 |
GroupedDBID | --- 18M 29B 2FS 2WC 34G 39C 53G 5GY 5RE 5VS 6J9 AAFWJ AAJMC AAYXX ABOCM ACGFO ACIWK ACPRK ACSVP ADBBV ADCOW ADNWM AENEX AFHIN AFOSN AFRAH AFUMD ALMA_UNASSIGNED_HOLDINGS BAWUL BR6 BTFSW CITATION CS3 DIK DU5 E3Z EBS EJD F5P FRP GX1 H13 IH2 KQ8 L7B LSO OK1 P0W P2P QTD RCR RHI RNS SJN TR2 W2D W8F WOQ YKV CGR CUY CVF ECM EIF NPM RHF 7X8 5PM |
ID | FETCH-LOGICAL-c477t-65ecf872cbec9dbf0e15f984b730504c63d1e01e0272813acbe11e81f24668423 |
ISSN | 1078-0432 1557-3265 |
IngestDate | Thu Aug 21 18:11:13 EDT 2025 Fri Sep 05 03:05:41 EDT 2025 Wed Feb 19 02:30:38 EST 2025 Thu Apr 24 22:52:24 EDT 2025 Tue Jul 01 01:30:20 EDT 2025 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 3 |
Language | English |
License | 2018 American Association for Cancer Research. |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c477t-65ecf872cbec9dbf0e15f984b730504c63d1e01e0272813acbe11e81f24668423 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ORCID | 0000-0001-5722-2075 |
OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/6359971 |
PMID | 30352907 |
PQID | 2125311459 |
PQPubID | 23479 |
PageCount | 10 |
ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_6359971 proquest_miscellaneous_2125311459 pubmed_primary_30352907 crossref_primary_10_1158_1078_0432_CCR_18_2039 crossref_citationtrail_10_1158_1078_0432_CCR_18_2039 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2019-02-01 |
PublicationDateYYYYMMDD | 2019-02-01 |
PublicationDate_xml | – month: 02 year: 2019 text: 2019-02-01 day: 01 |
PublicationDecade | 2010 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States |
PublicationTitle | Clinical cancer research |
PublicationTitleAlternate | Clin Cancer Res |
PublicationYear | 2019 |
References | Colin (2022061019361331500_bib7) 2009; 104 The Cancer Genome Atlas Research Network (2022061019361331500_bib9) 2014; 507 O'Brien (2022061019361331500_bib34) 2011; 60 Wang (2022061019361331500_bib38) 2013; 2 Robertson (2022061019361331500_bib10) 2017; 171 Zehir (2022061019361331500_bib14) 2017; 23 Seisen (2022061019361331500_bib24) 2015; 67 Hurst (2022061019361331500_bib27) 2008; 27 Hafner (2022061019361331500_bib37) 2001; 20 Rouprêt (2022061019361331500_bib20) 2008; 54 Lindgren (2022061019361331500_bib26) 2012; 7 Win (2022061019361331500_bib8) 2012; 104 Ostrovnaya (2022061019361331500_bib17) 2015; 9 Loriot (2022061019361331500_bib29) 2018; 36 Moss (2022061019361331500_bib12) 2017; 72 Hampel (2022061019361331500_bib31) 2018; 4 Sfakianos (2022061019361331500_bib11) 2015; 68 Babjuk (2022061019361331500_bib2) 2017; 71 Green (2022061019361331500_bib4) 2013; 189 Grollman (2022061019361331500_bib6) 2007; 104 Cheng (2022061019361331500_bib28) 2018; 18 Jones (2022061019361331500_bib36) 2005; 11 Chiou (2022061019361331500_bib5) 2001; 153 Alexandrov (2022061019361331500_bib22) 2013; 500 Rosenberg (2022061019361331500_bib32) 2016; 387 Munoz (2022061019361331500_bib3) 2000; 164 Shen (2022061019361331500_bib15) 2016; 44 Liu (2022061019361331500_bib25) 2014; 13 Habuchi (2022061019361331500_bib35) 1993; 342 Iyer (2022061019361331500_bib18) 2013; 31 Rouprêt (2022061019361331500_bib21) 2018; 73 Audenet (2022061019361331500_bib30) 2012; 110 Siegel (2022061019361331500_bib1) 2018; 68 Alexandrov (2022061019361331500_bib23) 2013; 3 Middha (2022061019361331500_bib19) 2017 Cheng (2022061019361331500_bib13) 2015; 17 Iyer (2022061019361331500_bib33) 2017; 35 Niu (2022061019361331500_bib16) 2014; 30 31184534 - J Urol. 2019 Sep;202(3):456-457 |
References_xml | – volume: 67 start-page: 1122 year: 2015 ident: 2022061019361331500_bib24 article-title: A systematic review and meta-analysis of clinicopathologic factors linked to intravesical recurrence after radical nephroureterectomy to treat upper tract urothelial carcinoma publication-title: Eur Urol doi: 10.1016/j.eururo.2014.11.035 – volume: 36 start-page: 411 year: 2018 ident: 2022061019361331500_bib29 article-title: Erdafitinib (ERDA; JNJ-42756493), a pan-fibroblast growth factor receptor (FGFR) inhibitor, in patients (pts) with metastatic or unresectable urothelial carcinoma (mUC) and FGFR alterations (FGFRa): Phase 2 continuous versus intermittent dosing publication-title: J Clin Oncol doi: 10.1200/JCO.2018.36.6_suppl.411 – volume: 11 start-page: 6512 year: 2005 ident: 2022061019361331500_bib36 article-title: Molecular evidence supporting field effect in urothelial carcinogenesis publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-05-0891 – volume: 7 start-page: e38863 year: 2012 ident: 2022061019361331500_bib26 article-title: Integrated genomic and gene expression profiling identifies two major genomic circuits in urothelial carcinoma publication-title: PLoS One doi: 10.1371/journal.pone.0038863 – volume: 30 start-page: 1015 year: 2014 ident: 2022061019361331500_bib16 article-title: MSIsensor: microsatellite instability detection using paired tumor–normal sequence data publication-title: Bioinformatics doi: 10.1093/bioinformatics/btt755 – volume: 500 start-page: 415 year: 2013 ident: 2022061019361331500_bib22 article-title: Signatures of mutational processes in human cancer publication-title: Nature doi: 10.1038/nature12477 – volume: 73 start-page: 111 year: 2018 ident: 2022061019361331500_bib21 article-title: European Association of Urology guidelines on upper urinary tract urothelial carcinoma: 2017 update publication-title: Eur Urol doi: 10.1016/j.eururo.2017.07.036 – volume: 44 start-page: e131 year: 2016 ident: 2022061019361331500_bib15 article-title: FACETS: allele-specific copy number and clonal heterogeneity analysis tool for high-throughput DNA sequencing publication-title: Nucleic Acids Res doi: 10.1093/nar/gkw520 – volume: 35 start-page: 4511 year: 2017 ident: 2022061019361331500_bib33 article-title: Mismatch repair (MMR) detection in urothelial carcinoma (UC) and correlation with immune checkpoint blockade (ICB) response publication-title: J Clin Oncol doi: 10.1200/JCO.2017.35.15_suppl.4511 – volume: 153 start-page: 411 year: 2001 ident: 2022061019361331500_bib5 article-title: Incidence of transitional cell carcinoma and arsenic in drinking water: a follow-up study of 8,102 residents in an arseniasis-endemic area in northeastern Taiwan publication-title: Am J Epidemiol doi: 10.1093/aje/153.5.411 – volume: 104 start-page: 12129 year: 2007 ident: 2022061019361331500_bib6 article-title: Aristolochic acid and the etiology of endemic (Balkan) nephropathy publication-title: Proc Natl Acad Sci USA doi: 10.1073/pnas.0701248104 – volume: 17 start-page: 251 year: 2015 ident: 2022061019361331500_bib13 article-title: Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): a hybridization capture-based next-generation sequencing clinical assay for solid tumor molecular oncology publication-title: J Mol Diagn doi: 10.1016/j.jmoldx.2014.12.006 – volume: 110 start-page: E583 year: 2012 ident: 2022061019361331500_bib30 article-title: A proportion of hereditary upper urinary tract urothelial carcinomas are misclassified as sporadic according to a multi-institutional database analysis: proposal of patient-specific risk identification tool publication-title: BJU Int doi: 10.1111/j.1464-410X.2012.11298.x – volume: 68 start-page: 7 year: 2018 ident: 2022061019361331500_bib1 article-title: Cancer statistics, 2018 publication-title: CA Cancer J Clin doi: 10.3322/caac.21442 – volume: 72 start-page: 641 year: 2017 ident: 2022061019361331500_bib12 article-title: Comprehensive genomic characterization of upper tract urothelial carcinoma publication-title: Eur Urol doi: 10.1016/j.eururo.2017.05.048 – volume: 171 start-page: 540 year: 2017 ident: 2022061019361331500_bib10 article-title: Comprehensive molecular characterization of muscle-invasive bladder cancer publication-title: Cell doi: 10.1016/j.cell.2017.09.007 – volume: 31 start-page: 3133 year: 2013 ident: 2022061019361331500_bib18 article-title: Prevalence and co-occurrence of actionable genomic alterations in high-grade bladder cancer publication-title: J Clin Oncol doi: 10.1200/JCO.2012.46.5740 – volume: 60 start-page: 703 year: 2011 ident: 2022061019361331500_bib34 article-title: Prevention of bladder tumours after nephroureterectomy for primary upper urinary tract urothelial carcinoma: a prospective, multicentre, randomised clinical trial of a single postoperative intravesical dose of mitomycin C (the ODMIT-C Trial) publication-title: Eur Urol doi: 10.1016/j.eururo.2011.05.064 – volume: 507 start-page: 315 year: 2014 ident: 2022061019361331500_bib9 article-title: Comprehensive molecular characterization of urothelial bladder carcinoma publication-title: Nature doi: 10.1038/nature12965 – volume: 189 start-page: 1214 year: 2013 ident: 2022061019361331500_bib4 article-title: Urothelial carcinoma of the bladder and the upper tract: disparate twins publication-title: J Urol doi: 10.1016/j.juro.2012.05.079 – volume: 387 start-page: 1909 year: 2016 ident: 2022061019361331500_bib32 article-title: Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial publication-title: Lancet doi: 10.1016/S0140-6736(16)00561-4 – volume: 23 start-page: 703 year: 2017 ident: 2022061019361331500_bib14 article-title: Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients publication-title: Nat Med doi: 10.1038/nm.4333 – volume: 4 start-page: 806 year: 2018 ident: 2022061019361331500_bib31 article-title: Assessment of tumor sequencing as a replacement for lynch syndrome screening and current molecular tests for patients with colorectal cancer publication-title: JAMA Oncol doi: 10.1001/jamaoncol.2018.0104 – volume: 104 start-page: 1363 year: 2012 ident: 2022061019361331500_bib8 article-title: Risks of primary extracolonic cancers following colorectal cancer in lynch syndrome publication-title: J Natl Cancer Inst doi: 10.1093/jnci/djs351 – volume: 18 start-page: 527 year: 2018 ident: 2022061019361331500_bib28 article-title: Clinical tumour sequencing for precision oncology: time for a universal strategy publication-title: Nat Rev Cancer doi: 10.1038/s41568-018-0043-2 – volume: 13 start-page: 1109 year: 2014 ident: 2022061019361331500_bib25 article-title: Clinical significance of fibroblast growth factor receptor-3 mutations in bladder cancer: a systematic review and meta-analysis publication-title: Genet Mol Res doi: 10.4238/2014.February.20.12 – volume: 104 start-page: 1436 year: 2009 ident: 2022061019361331500_bib7 article-title: Environmental factors involved in carcinogenesis of urothelial cell carcinomas of the upper urinary tract publication-title: BJU Int doi: 10.1111/j.1464-410X.2009.08838.x – volume: 3 start-page: 246 year: 2013 ident: 2022061019361331500_bib23 article-title: Deciphering signatures of mutational processes operative in human cancer publication-title: Cell Rep doi: 10.1016/j.celrep.2012.12.008 – volume: 164 start-page: 1523 year: 2000 ident: 2022061019361331500_bib3 article-title: Upper tract urothelial neoplasms: incidence and survival during the last 2 decades publication-title: J Urol doi: 10.1016/S0022-5347(05)67019-X – volume: 68 start-page: 970 year: 2015 ident: 2022061019361331500_bib11 article-title: Genomic characterization of upper tract urothelial carcinoma publication-title: Eur Urol doi: 10.1016/j.eururo.2015.07.039 – volume: 71 start-page: 447 year: 2017 ident: 2022061019361331500_bib2 article-title: EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2016 publication-title: Eur Urol doi: 10.1016/j.eururo.2016.05.041 – volume: 54 start-page: 1226 year: 2008 ident: 2022061019361331500_bib20 article-title: Upper urinary tract urothelial cell carcinomas and other urological malignancies involved in the hereditary nonpolyposis colorectal cancer (lynch syndrome) tumor spectrum publication-title: Eur Urol doi: 10.1016/j.eururo.2008.08.008 – volume: 9 start-page: 1533 year: 2015 ident: 2022061019361331500_bib17 article-title: Using somatic mutation data to test tumors for clonal relatedness publication-title: Ann Appl Stat doi: 10.1214/15-AOAS836 – volume: 27 start-page: 2716 year: 2008 ident: 2022061019361331500_bib27 article-title: Inactivation of the Rb pathway and overexpression of both isoforms of E2F3 are obligate events in bladder tumours with 6p22 amplification publication-title: Oncogene doi: 10.1038/sj.onc.1210934 – volume: 2 start-page: 412 year: 2013 ident: 2022061019361331500_bib38 article-title: Comparison of the clonality of urothelial carcinoma developing in the upper urinary tract and those developing in the bladder publication-title: Springerplus doi: 10.1186/2193-1801-2-412 – start-page: 1 year: 2017 ident: 2022061019361331500_bib19 article-title: Reliable pan-cancer microsatellite instability assessment by using targeted next-generation sequencing data publication-title: JCO Precis Oncol – volume: 20 start-page: 4910 year: 2001 ident: 2022061019361331500_bib37 article-title: Evidence for oligoclonality and tumor spread by intraluminal seeding in multifocal urothelial carcinomas of the upper and lower urinary tract publication-title: Oncogene doi: 10.1038/sj.onc.1204671 – volume: 342 start-page: 1087 year: 1993 ident: 2022061019361331500_bib35 article-title: Metachronous multifocal development of urothelial cancers by intraluminal seeding publication-title: Lancet doi: 10.1016/0140-6736(93)92066-3 – reference: 31184534 - J Urol. 2019 Sep;202(3):456-457 |
SSID | ssj0014104 |
Score | 2.6398034 |
Snippet | To investigate genomic differences between urothelial carcinomas of the upper tract (UTUC) and bladder (UCB), with a focus on defining the clonal relatedness... |
SourceID | pubmedcentral proquest pubmed crossref |
SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source |
StartPage | 967 |
SubjectTerms | Aged Biomarkers, Tumor - genetics Carcinoma, Transitional Cell - genetics Clone Cells - metabolism Colorectal Neoplasms, Hereditary Nonpolyposis - genetics Female Genetic Predisposition to Disease - genetics Genomics - methods High-Throughput Nucleotide Sequencing - methods Humans Male Middle Aged Mutation Prospective Studies Receptor, Fibroblast Growth Factor, Type 3 - genetics Tumor Suppressor Protein p53 - genetics Urinary Bladder - metabolism Urinary Bladder - pathology Urinary Bladder Neoplasms - genetics Urinary Tract - metabolism Urinary Tract - pathology |
Title | Clonal Relatedness and Mutational Differences between Upper Tract and Bladder Urothelial Carcinoma |
URI | https://www.ncbi.nlm.nih.gov/pubmed/30352907 https://www.proquest.com/docview/2125311459 https://pubmed.ncbi.nlm.nih.gov/PMC6359971 |
Volume | 25 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3da9swEBdbB2MvY9_rvtBgb8GZZUuR9di5Kd3WdjASyJuILYUGMie4CYX-9buTZDtZA-sGwQRFthzdT6fTfRLyaar4DHYNGwllBhHncNyZKmUjVjBZFgZ2LIMHxfOLwemYf5uISWcucNEl66Jf3uyNK_kfqkIb0BWjZP-Bsu1DoQG-A33hChSG651onC-cHs85tFnjmJbzm9isGxXfcah_gn5XjUvWeLWyNWY1L713-ZcFcp-6N64xGmuBKvQcKwxVy8Czm0QGTRBliUipeyFPUKtPPsIsmd62geKwM8HL5fyqQ9_ltL52BQaAX_2atw43uTc6DTfwR22ndz1eVlhP2DYhRb1RULwGJQXGRbUOH4GvCuBliS8L0bd72gIz9lHQAXTpFmdVvmrHbY4vMqd8wETBPE36ef4zYggTnyNpN8P2xQ99Mj4706PhZHSfPEgkyFsoSH_93lqeOHMlJ9uXC1FfMMznvYPsyjO3Dil_-tpuCS-jJ-RxOHXQIw-hp-SerZ6Rh-fBr-I5KTyS6BaSKECDdkiiW0iiAUnUIYk6JLnuAUm0QxJtkfSCjE-Go_w0CtU3opJLuY4GwpazTCYlrHJlillsmZipjBewJ4iYl4PUMBvDJ5FJxtIp9GPMZgyW_gCNu-lLclAtK_ua0DK2wsjYFMD-uShEoYzBOgGZUXEyS-Qh4c0c6jKkpscKKQvtjqgi0zj1Gqdew9Rrlmmc-kPSb29b-dwsf7vhY0MgDVwUTWPTyi43VxoEONiMGBfQ55UnWPvIFFMGqxjeUu6Qsu2AGdp3f6nmly5TO0jzSkn25g7jviWPuoXzjhys6419D_LuuvjgAPobRCyovw |
linkProvider | Flying Publisher |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Clonal+Relatedness+and+Mutational+Differences+between+Upper+Tract+and+Bladder+Urothelial+Carcinoma&rft.jtitle=Clinical+cancer+research&rft.au=Audenet%2C+Fran%C3%A7ois&rft.au=Isharwal%2C+Sumit&rft.au=Cha%2C+Eugene+K&rft.au=Donoghue%2C+Mark+T+A&rft.date=2019-02-01&rft.issn=1557-3265&rft.eissn=1557-3265&rft.volume=25&rft.issue=3&rft.spage=967&rft_id=info:doi/10.1158%2F1078-0432.CCR-18-2039&rft.externalDBID=NO_FULL_TEXT |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1078-0432&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1078-0432&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1078-0432&client=summon |